01:30 PM EDT, 05/01/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We lower our target price to $973 from $1,045, on 33.2x our 2026 EPS estimate, a discount to LLY's five-year historical forward P/E average. We cut our 2025 EPS estimate to $22.25 from $24.02 and keep our 2026 EPS estimate at $29.35. In our view, Eli Lilly ( LLY ) delivered a robust start to 2025, with Q1 revenue surging by 45% Y/Y, primarily driven by exceptional performance from its GLP-1 products, Mounjaro (+113% Y/Y, $3.8B) and Zepbound ($2.3B vs. $517M). We expect solid sales growth in GLP-1 products, both in the U.S. and overseas, to continue this year due to volume growth. Post Q1 earnings, we see a top-line revenue growth of 32% Y/Y, largely above U.S. biopharma peers. We think shares are trading down today due to the bottom-line miss and CVS's decision to partner with rival Novo Nordisk to increase access of Wegovy to its members starting July 1. Yet, during the earnings call today, management seemed confident in maintaining the sales guidance despite the announcement.